RU2020114890A - Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина - Google Patents

Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина Download PDF

Info

Publication number
RU2020114890A
RU2020114890A RU2020114890A RU2020114890A RU2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A
Authority
RU
Russia
Prior art keywords
linagliptin
formula
crystalline form
intermediate compound
prepare
Prior art date
Application number
RU2020114890A
Other languages
English (en)
Russian (ru)
Other versions
RU2020114890A3 (cg-RX-API-DMAC7.html
Inventor
Венката Рагхавендрачарьюлу ПАЛЛЕ
Шанмугхасами РАДЖМАХЕНДРА
Дхаршан Джаккали ЧАНДРЕГОВДА
Тангарасу ПОННУСАМИ
Original Assignee
Биокон Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биокон Лимитед filed Critical Биокон Лимитед
Publication of RU2020114890A publication Critical patent/RU2020114890A/ru
Publication of RU2020114890A3 publication Critical patent/RU2020114890A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2020114890A 2017-09-27 2018-09-27 Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина RU2020114890A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201741034292 2017-09-27
IN201741034292 2017-09-27
PCT/IB2018/057484 WO2019064214A1 (en) 2017-09-27 2018-09-27 INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN

Publications (2)

Publication Number Publication Date
RU2020114890A true RU2020114890A (ru) 2021-10-27
RU2020114890A3 RU2020114890A3 (cg-RX-API-DMAC7.html) 2022-08-10

Family

ID=65903063

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020114890A RU2020114890A (ru) 2017-09-27 2018-09-27 Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина

Country Status (10)

Country Link
US (1) US11040974B2 (cg-RX-API-DMAC7.html)
JP (1) JP2020535193A (cg-RX-API-DMAC7.html)
KR (1) KR20200092946A (cg-RX-API-DMAC7.html)
CN (1) CN111511743A (cg-RX-API-DMAC7.html)
AU (1) AU2018343236A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020005964A2 (cg-RX-API-DMAC7.html)
CA (1) CA3076980A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020004050A (cg-RX-API-DMAC7.html)
RU (1) RU2020114890A (cg-RX-API-DMAC7.html)
WO (1) WO2019064214A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684026A (zh) * 2019-10-24 2020-01-14 扬子江药业集团上海海尼药业有限公司 一种利格列汀的工业化制备方法
CN110872292B (zh) * 2019-11-30 2022-01-25 江苏君若药业有限公司 一条合成糖尿病药物利拉利汀的路线
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
IN2013MU02055A (cg-RX-API-DMAC7.html) * 2013-06-18 2015-07-03 Cadila Healthcare Ltd
WO2015011609A1 (en) * 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof

Also Published As

Publication number Publication date
JP2020535193A (ja) 2020-12-03
BR112020005964A2 (pt) 2020-10-06
WO2019064214A1 (en) 2019-04-04
KR20200092946A (ko) 2020-08-04
US11040974B2 (en) 2021-06-22
US20200354363A1 (en) 2020-11-12
CA3076980A1 (en) 2019-04-04
CN111511743A (zh) 2020-08-07
MX2020004050A (es) 2020-11-06
AU2018343236A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
FI3964510T3 (fi) Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö
JP2021530565A5 (cg-RX-API-DMAC7.html)
RU2017106602A (ru) Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1-4-дигидро-1,6-нафтиридин-3-карбоксамида и его очистки для применения в качестве фармацевтического активного ингредиента
RU2017102355A (ru) Способ получения конденсированного гетероциклического соединения
JP2015532645A5 (cg-RX-API-DMAC7.html)
JP2017222671A5 (cg-RX-API-DMAC7.html)
HRP20240695T1 (hr) Novi polimorfi kalcijeve soli kao protuupalna, imunomodulatorna i anti-proliferacijska sredstva
JP2019504103A5 (cg-RX-API-DMAC7.html)
RU2017134709A (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
RU2021102393A (ru) Твердые формы пладиенолидпиридиновых соединений и способы их применения
CN104592183B (zh) N-酰基-n-间氟苄基-8-氨基香豆素类化合物及其制备与除草用途
JP2018534243A5 (cg-RX-API-DMAC7.html)
CN111278820A (zh) 一种吡啶酮化合物的晶型、盐型及其制备方法
RU2019118993A (ru) Производное азациклобутилтриазола с конденсированной кольцевой группой, способ его получения и его применение в медицине
JP2020535193A5 (cg-RX-API-DMAC7.html)
MX2024000326A (es) Nuevas formas polimorficas de ciclo (-his-pro).
JP2012515709A5 (cg-RX-API-DMAC7.html)
CN104829574A (zh) 一种8-溴吡喃衍生物的制备方法
CN104829576A (zh) 一种7-氟吡喃衍生物的制备方法
JP2018509421A5 (cg-RX-API-DMAC7.html)
EP2963007A1 (en) Synthesis of Calebin-A and its biologically active analogs
RU2015135184A (ru) Способ получения соединения пиридазинона и промежуточных продуктов для его получения
RU2019101109A (ru) Твердые формы ингибитора ttk
ZA202201469B (en) Continuous process for preparing the crystalline form ii of sotagliflozin
WO2017081702A2 (en) A process for preparation of enzalutamide